Physician profile
Dionne M Rouselle
NPI 1689669152
$3,688.78
in general payments reported to CMS, 2019-2025
32 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $244 · 2021: $389 · 2022: $474 · 2023: $838 · 2024: $699 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $695.45 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Pfizer INC. | $427.12 | 2021-2025 | |
| Hologic Sales and Service, LLC | $319.40 | 2022-2025 | Acessa Provu System, Myosure Tissue Removal Device, Coolseal Generator |
| Mayne Pharma Commercial LLC | $270.84 | 2021-2024 | |
| Novo Nordisk INC | $264.45 | 2022-2024 | Wegovy |
| Daiichi Sankyo INC. | $255.80 | 2019-2025 | Injectafer |
| Intuitive Surgical, INC. | $255.45 | 2019-2021 | |
| Astellas Pharma US INC | $165.17 | 2023-2025 | Veozah, Myrbetriq |
| Channel Medsystems, INC. | $140.31 | 2023 | |
| Sumitomo Pharma America, INC. | $122.12 | 2024-2025 | Myfembree |
| Biogen, INC. | $96.71 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $80.53 | 2024-2025 | Nuvessa, Slynd, Tyblume |
| Shield Therapeutics INC | $76.16 | 2023-2025 | Accrufer |
| Organon LLC | $67.45 | 2024 | |
| Therapeuticsmd, INC. | $62.02 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $46.71 | 2019-2021 | |
| Avion Pharmaceuticals | $43.32 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $38.38 | 2019-2022 | |
| Gen-Probe, INC. | $29.53 | 2019 | |
| Agile Therapeutics, INC. | $29.17 | 2022-2023 | Twirla |
| Allergan, INC. | $25.39 | 2019-2020 | |
| Optumhealth Care Solutions, LLC | $21.62 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Duchesnay USA Incorporated | $20.91 | 2019 | |
| Millicent US INC | $18.15 | 2024 | Intrarosa, Femring |
| Kowa Pharmaceuticals America, INC. | $17.87 | 2023 | Seglentis |
| Merck Sharp & Dohme LLC | $17.65 | 2019 | |
| Convatec INC. | $15.45 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.05 | 2019 | |
| Medtronic, INC. | $14.22 | 2023 | Truclear |
| Evofem Biosciences, INC. | $13.01 | 2022 | |
| Scynexis, INC. | $12.20 | 2022 | |
| Minerva Surgical, INC | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dionne Rouselle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.